Who is sponsoring NCT07084896?

NCT07084896 is sponsored by GlaxoSmithKline.

What condition does NCT07084896 study?

NCT07084896 studies Multiple Myeloma.

What drugs are being tested in NCT07084896?

Interventions: Belantamab mafodotin, Nirogacestat.

What is the status of NCT07084896?

NCT07084896 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2025-07-25 · How we verify

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

NCT07084896 PHASE1, PHASE2 ACTIVE_NOT_RECRUITING

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE1, PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	106
Start date	Mon Jun 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Mar 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Multiple Myeloma

Interventions

Belantamab mafodotin
Nirogacestat

Countries

France, Netherlands, Russia, Greece, Sweden, Germany, Poland, Norway, South Korea, Canada, Australia, United States, Spain